Mirikizumab (Omvoh)

Canada’s Drug Agency (CDA-AMC) recommends that Omvoh be reimbursed by public drug plans for the treatment of moderately to severely active Crohn disease (CD) in cases in which conventional treatment or biologic therapies have led to an inadequate response, a loss of response, or intolerable side effects, if certain conditions are met. Omvoh should only be covered according to reimbursement eligibility criteria used by each of the public drug plans for other advanced therapies for the treatment of adults with moderately to severely active CD who have had an inadequate response, a loss of response, or intolerance to either conventional therapy or a biologic treatment. Omvoh should only be reimbursed if it is prescribed according to the criteria used by each of the public drug plans for other advanced therapies and if the cost of Omvoh is reduced so it does not cost the drug programs more than the least costly available advanced therapy reimbursed for the treatment of adult patients with moderately to severely active CD.